Form 8-K - Current report:
SEC Accession No. 0001493152-25-006481
Filing Date
2025-02-13
Accepted
2025-02-13 17:20:23
Documents
18
Period of Report
2025-02-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 68503
2 ex3-1.htm EX-3.1 119647
3 ex4-2.htm EX-4.2 138160
4 ex10-1.htm EX-10.1 267775
5 ex99-1.htm EX-99.1 21797
6 ex99-1_001.jpg GRAPHIC 5134
  Complete submission text file 0001493152-25-006481.txt   921379

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE mtnb-20250213.xsd EX-101.SCH 3039
8 XBRL LABEL FILE mtnb-20250213_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE mtnb-20250213_pre.xml EX-101.PRE 22375
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3837
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 25621687
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)